Kyi Lai Yin Swe
Kyi Lai Yin Swe has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia Georgakopoulou
Cancer Research UK Scotland Institute, Glasgow, G61 1BD, UK
94 shared publications - Karen Blyth
Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
93 shared publications - Toshiyasu Suzuki
Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
93 shared publications - Adrian Hayday
Francis Crick Institute, London, UK
92 shared publications - Amy Lawlor
Cancer Research UK Scotland Institute, Glasgow, G61 1BD, United Kingdom
92 shared publications - Anett Jandke
Department of Biomedicine, Immunobiology, University and University Hospital of Basel, Basel, Switzerland
92 shared publications
Latest Publications
- Open Access
Preclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinoma
Background & Aims: Hepatocellular carcinoma (HCC), a predominant form of liver cancer, remains a significant clinical unmet need. Given that 30–50% of HCC cases harbour mutations in the Wnt/β-catenin signalling pathway, targeting this cascade represents a promising therapeutic strategy. However, the clinical translation of Wnt inhibitors has been hindered by severe adverse events observed in preclinical models and early-phase clinical trials, primarily due to the essential role of Wnt signalling in maintaining normal tissues such as the intestine and bone. Methods: We examined the efficacy of Tegavivint, a first-in-class Wnt pathway inhibitor that targets TBL1, against HCC to elucidate its underlying mechanism of action. We evaluated the dose-response of Tegavivint and its effects on the cell cycle, apoptosis, and Wnt target gene expression using HepG2, HUH6, and HUH7 cell lines in vitro . Furthermore, we employed an orthotopic xenograft transplant model using HepG2 cells in immunodeficient mice to assess the safety profile and on-target anti-cancer efficacy of Tegavivint in vivo . Results: Tegavivint exhibited potent Wnt pathway-suppressing effects in cancer cells with constitutive Wnt pathway activation. Notably, Tegavivint displayed robust anti-tumour activity across a broad range of HCC cell lines, regardless of their Wnt pathway activation status. While Tegavivint inhibited the Wnt pathway and triggered the activation of apoptotic pathways in most cell lines, our findings suggest that it also can induce cell death by activating alternative non-apoptotic pathways in apoptosis-resistant cancer cells. In an orthotopic transplant mouse model, Tegavivint significantly downregulated Wnt pathway target genes, inhibited cell proliferation, induced apoptosis and suppressed growth in tumours. Conclusions: Taken together, our data establish a robust foundation for evaluating Tegavivint as a novel therapeutic option, specifically tailored for HCC patients harbouring Wnt-driven hepatic malignancies.
Open AccessPreclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinoma
Background & Aims: Hepatocellular carcinoma (HCC), a predominant form of liver cancer, remains a significant clinical unmet need. Given that 30–50% of HCC cases harbour mutations in the Wnt/β-catenin signalling pathway, targeting this cascade represents a promising therapeutic strategy. However, the clinical translation of Wnt inhibitors has been hindered by severe adverse events observed in preclinical models and early-phase clinical trials, primarily due to the essential role of Wnt signalling in maintaining normal tissues such as the intestine and bone. Methods: We examined the efficacy of Tegavivint, a first-in-class Wnt pathway inhibitor that targets TBL1, against HCC to elucidate its underlying mechanism of action. We evaluated the dose-response of Tegavivint and its effects on the cell cycle, apoptosis, and Wnt target gene expression using HepG2, HUH6, and HUH7 cell lines in vitro . Furthermore, we employed an orthotopic xenograft transplant model using HepG2 cells in immunodeficient mice to assess the safety profile and on-target anti-cancer efficacy of Tegavivint in vivo . Results: Tegavivint exhibited potent Wnt pathway-suppressing effects in cancer cells with constitutive Wnt pathway activation. Notably, Tegavivint displayed robust anti-tumour activity across a broad range of HCC cell lines, regardless of their Wnt pathway activation status. While Tegavivint inhibited the Wnt pathway and triggered the activation of apoptotic pathways in most cell lines, our findings suggest that it also can induce cell death by activating alternative non-apoptotic pathways in apoptosis-resistant cancer cells. In an orthotopic transplant mouse model, Tegavivint significantly downregulated Wnt pathway target genes, inhibited cell proliferation, induced apoptosis and suppressed growth in tumours. Conclusions: Taken together, our data establish a robust foundation for evaluating Tegavivint as a novel therapeutic option, specifically tailored for HCC patients harbouring Wnt-driven hepatic malignancies.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Identification of a WNT responsive element (WRE) in the HNF4G genomic locus.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Identification of a WNT responsive element (WRE) in the HNF4G genomic locus.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Disruption of WNT gradient in normal intestinal villi reduces gamma delta T cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Disruption of WNT gradient in normal intestinal villi reduces gamma delta T cells
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Clinicopathological characteristics of colon cancer patient cohorts.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Clinicopathological characteristics of colon cancer patient cohorts.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
WNT expression is independent of BTN3A1 and BTN2A1
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
WNT expression is independent of BTN3A1 and BTN2A1
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Correlation between gut-specific transcription factors, gamma delta T cell density and BTNL genes in human tumors
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Correlation between gut-specific transcription factors, gamma delta T cell density and BTNL genes in human tumors
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Deletion of Apc in organoids increases WNT target genes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Deletion of Apc in organoids increases WNT target genes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Impact of Btnl1 and Btnl6 expression on Vgamma7+ cells and the tumor microenvironment
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Impact of Btnl1 and Btnl6 expression on Vgamma7+ cells and the tumor microenvironment
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Knockdown of Cdx1, Cdx2 and Hnf4a fails to influence organoid morphology or expression of Btnl genes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Knockdown of Cdx1, Cdx2 and Hnf4a fails to influence organoid morphology or expression of Btnl genes